In addition, other strategies have been used to enhance CAR-T cell function in TME, including inhibition of inhibitory soluble molecules such as IDO, adenosine and VEGF, and protection from immunosuppression of non-tumor cells, such as MDSCs and TAMs. The gene discussed is VEGFA; the disease is neoplasm.